Sanofi has entered into a significant $1.53 billion global licensing agreement with Sino Biopharmaceutical for rovadicitinib, a first-in-class dual JAK/ROCK inhibitor. Under the terms of the deal, Sanofi will provide an upfront payment of $135 million, with an additional $1.395 billion earmarked for potential regulatory and commercial milestones, plus tiered royalties.
Rovadicitinib stands out as the first oral inhibitor to target both JAK and ROCK pathways, delivering unique anti-inflammatory and anti-fibrotic effects. While the drug recently received its first approval in China for myelofibrosis, Sanofi’s primary interest lies in its “core value” for treating chronic graft-versus-host disease (cGVHD). The FDA has already cleared the asset to enter Phase 2 clinical trials in the United States.
This partnership further strengthens Sanofi’s specialty care portfolio, mirroring its recent $9.5 billion acquisition of Blueprint Medicines in 2025. For Sino Biopharm, this deal represents a milestone in out-licensing innovative assets to major Western pharmaceutical leaders, highlighting the accelerating trend of cross-border deals originating from China’s biotech sector.